BACKGROUND: Faecal microbiota transplantation (FMT) is an established treatment for Clostridioides difficile infection and is under investigation for other conditions. The availability of suitable donors and the logistics of fresh stool preparation present challenges, making frozen, biobanked stools an attractive alternative. AIMS: This study aimed to evaluate the long-term viability of bacterial populations in faecal samples stored at -80°C for up to 12 months, supporting the feasibility of using frozen grafts for FMT. METHODS: Fifteen faecal samples from nine healthy donors were processed, mixed with cryoprotectants and stored at -80°C. Samples were assessed at baseline and after 3, 6 and 12 months using quantitative culturing methods to determine the concentration of live bacteria. RESULTS: Quantitative analysis showed no significant decrease in bacterial viability over the 12-month period for both aerobic and anaerobic cultures (p = 0.09). At all timepoints, the coefficients of variability in colony-forming unit (CFU) counts were greater between samples (102 ± 21% and 100 ± 13% for aerobic and anaerobic cultures, respectively) than the variability between measurements of the same sample (30 ± 22% and 30 ± 19%). CONCLUSIONS: The study confirmed that faecal microbiota can be preserved with high viability in deep-freeze storage for up to a year, making allogenic FMT from biobanked samples a viable and safer option for patients. However, a multidonor approach may be beneficial to mitigate the risk of viability loss in any single donor sample.

Department of Anaesthesia and Intensive Care Medicine The 3rd Faculty of Medicine Charles University and Kralovske Vinohrady University Hospital Prague Czech Republic

Department of Microbiology The 3rd Faculty of Medicine Charles University and Kralovske Vinohrady University Hospital Prague Czech Republic

Division of Gastroenterology Department of Medicine Kralovske Vinohrady University Hospital Prague Czech Republic

Zobrazit více v PubMed

Beneš J., Stebel R., Musil V., Krůtová M., Vejmelka J., and Kohout P., “Aktualizovaný doporučený postup pro léčbu nemocných s kolitidou vyvolanou Clostridioides difficile” [Updated Recommended Procedure for Treating Patients with Clostridioides difficile‐Induced Colitis]. Doporučený postup Společnosti infekčního lékařství ČLS JEP, issued on 20. 9.2022.

Kelly C. R., Fischer M., Allegretti J. R., et al., “ACG Clinical Guidelines: Prevention, Diagnosis, and Treatment of Clostridioides difficile Infections,” The American Journal of Gastroenterology 116 (2021): 1124–1147. PubMed

Osman M., Budree S., Kelly C. R., et al., “Effectiveness and Safety of Faecal Microbiota Transplantation for Clostridioides difficile Infection: Results From a 5344‐Patient Cohort Study,” Gastroenterology 163, no. 1 (2022): 319–322, 10.1053/j.gastro.2022.03.051. Epub 2022 Apr 7. PMID: 35398345. PubMed DOI

Gregory J. C., Buffa J. A., Org E., et al., “Transmission of Atherosclerosis Susceptibility with Gut Microbial Transplantation,” Journal of Biological Chemistry 290 (2015): 5647–5660. PubMed PMC

Vrieze A., van Nood E., Holleman F., et al., “Transfer of Intestinal Microbiota from Lean Donors Increases Insulin Sensitivity in Individuals with Metabolic Syndrome,” Gastroenterology 143 (2012): 913–916.e7. PubMed

Oka A. and Sartor R. B., “Microbial‐Based and Microbial‐Targeted Therapies for Inflammatory Bowel Diseases,” Digestive Diseases and Sciences 65 (2020): 757–788. PubMed PMC

Caldeira L. F., Borba H. H., Tonin F. S., Wiens A., Fernandez‐Llimos F., and Pontarolo R., “Faecal Microbiota Transplantation in Inflammatory Bowel Disease Patients: A Systematic Review and Meta‐Analysis,” PLoS One 15, no. 9 (2020): e0238910, 10.1371/journal.pone.0238910. PMID: 32946509; PMCID: PMC7500646. PubMed DOI PMC

Lee C. H., Steiner T., Petrof E. O., et al., “Frozen vs. Fresh Faecal Microbiota Transplantation and Clinical Resolution of Diarrhea in Patients with Recurrent Clostridium difficile Infection: A Randomized Clinical Trial,” Journal of the American Medical Association 315, no. 2 (2016): 142–149, 10.1001/jama.2015.18098. PMID: 26757463. PubMed DOI

Tang G., Yin W., and Liu W., “Is Frozen Faecal Microbiota Transplantation As Effective as Fresh Faecal Microbiota Transplantation in Patients with Recurrent or Refractory Clostridium difficile Infection: A Meta‐Analysis,” Diagnostic Microbiology and Infectious Disease 88, no. 4 (2017): 322–329. PubMed

NDFB: Nederlandse Donor Feces Bank. [Dutch Donor Feces Bank]. https://www.ndfb.nl/.

OPENBIOME. https://openbiome.org/microbiome‐education/whitepapers.

Terveer E. M., van Beurden Y. H., Goorhuis A., et al., “How to: Establish and Run a Stool Bank,” Clinical Microbiology and Infection 23, no. 12 (2017): 924–930, 10.1016/j.cmi.2017.05.015. Epub 2017 May 19. PMID: 28529025. PubMed DOI

Cammarota G., Ianiro G., Kelly C. R., et al., “International Consensus Conference on Stool Banking for Faecal Microbiota Transplantation in Clinical Practice,” Gut 68, no. 12 (2019): 2111–2121, 10.1136/gutjnl-2019-319548. Epub 2019 Sep 28. PMID: 31563878; PMCID: PMC6872442. PubMed DOI PMC

Keller J. J., Ooijevaar R. E., Hvas C. L., et al., “A Standardized Model for Stool Banking for Faecal Microbiota Transplantation: A Consensus Report from a Multidisciplinary UEG Working Group,” United European Gastroenterology Journal 9 (2021): 229–247. PubMed PMC

Use of Frozen Preparation in the Treatment of Colitis Caused by CLDI; Legislation.

Polívková S., Vojtilová L., Husa P., and Beneš J., “Doporučený postup fekální bakterioterapie pro léčbu rekurentní klostridiové kolitidy” [Recommended Procedure for Faecal Bacteriotherapy for the Treatment of Recurrent Clostridium difficile Colitis]. Doporučený postup Společnosti infekčního lékařství České lékařské společnosti J. E. Purkyně. Issued: April 2018.

EMA/204935/2022 “Faecal Microbiota Transplantation EU‐IN Horizon Scanning Report June 2022.” [Online] Available at: https://www.ema.europa.eu/en/documents/report/faecal‐microbiota‐transplantation‐eu‐horizon‐scanning‐report_en.pdf.

FDA‐2013‐D‐0811 “Enforcement Policy Regarding Investigational New Drug Requirements for Use of Faecal Microbiota for Transplantation to Treat Clostridium difficile Infection Not Responsive to Standard Therapies. Guidance for Industry.” 2022. [Online] Available at: https://www.fda.gov/regulatory‐information/search‐fda‐guidance‐documents/enforcement‐policy‐regarding‐investigational‐new‐drug‐requirements‐use‐faecal‐microbiota.

Scheeler A., “Where Stool Is a Drug: International Approaches to Regulating the Use of Faecal Microbiota for Transplantation,” The Journal of Law, Medicine & Ethics 47, no. 4 (2019): 524–540, 10.1177/1073110519897729. PubMed DOI

Řehořová V., Cibulková I., Soukupová H., and Duška F., “Multi‐Donor Faecal Microbial Transplantation for Critically Ill Patients: Rationale and Standard Operating Procedure,” Future Pharmacology 2 (2022): 55–63, 10.3390/futurepharmacol2010005. DOI

Papanicolas L. E., Choo J. M., Wang Y., et al., “Bacterial Viability in Faecal Transplants: Which Bacteria Survive?” eBioMedicine 41 (2019): 509–516, 10.1016/j.ebiom.2019.02.023. PMID: 30796005; PMCID: PMC6500792. PubMed DOI PMC

Varga A., Kocsis B., Sipos D., et al., “How to Apply FMT more Effectively, Conveniently and Flexible – A Comparison of FMT Methods,” Frontiers in Cellular and Infection Microbiology 11 (2021): 657320, 10.3389/fcimb.2021.657320. PMID: 34150673; PMCID: PMC8213398. PubMed DOI PMC

Vigvári S., Sipos D., Solt J., et al., “Faecal Microbiota Transplantation for Clostridium difficile Infection Using a Lyophilized Inoculum from Non‐related Donors: A Case Series Involving 19 Patients,” Acta Microbiologica et Immunologica Hungarica 66, no. 1 (2019): 69–78, 10.1556/030.64.2017.042. Epub 2017 Dec 14. PMID: 29239198. PubMed DOI